65,437 trials
Healthy Volunteers
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) for TAK-954 — 4; 3; 0 Participants
HIV · Substance Related Disorders
Primary: Number of Participants With HIV Viral Suppression — 97; 92; 74; 99 Participants
Attention-Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline at Day 15 in , ADHD Symptoms as Measured by Mean Swanson,Kotkin,Agler,M-Flynn, Pelham Rating Scale(SKAMP)-Combined Score Obtained From an Average of…
Cervical High Grade Squamous Intraepithelial Lesion
Primary: Cervical HSIL — 46; 39 Participants — p=.29
Hypertension · Vitamin D Deficiency
Primary: Change in Mean Blood Pressure From Baseline to 12 Weeks — 4.3 mmHg
Acute Kidney Injury
Primary: Incidence of Anticoagulant-related Nephropathy in the Cohort — 0 Percentage of participants
Ischemic Stroke
Primary: Revascularization Status Assessment at the End of the Trevo Retriever Procedure Using the Modified TICI Score — 1863 Participants
Drug Overdose · Opioid-Related Disorders · Drug Addiction
Primary: Medication-Assisted Treatment Enrollment — 7; 13 Participants
Periodontitis · Periodontal Pocket · Diabetes Mellitus
Primary: Probing Depth — 0.44; 0.50 mm — p=<0.05
Stroke · Hemiplegia, Spastic
Primary: Fugl-Meyer Assessment (FMA) — 3.45; 1.94 score on a scale
Bronchoscopy
Primary: Lowest Intraoperative Peripheral Oxygen Saturation (SpO2) — 94.7; 98.7 percentage of oxygen — p=0.09
B-cell Chronic Lymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia · Stage 0 Chronic Lymphocytic Leukemia
Primary: Maximum Tolerated Dose (MTD) of PGG Beta Glucan in Combination With Alemtuzumab and Rituximab Assessed by Analyzing the Number of Dose-limiting Toxicity Events (Phase I)…
Myelodysplastic Syndromes · Chronic Myelomonocytic Leukemia · Acute Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicity (DLT) (Phase lb) — 1; 3; 2 Participants
Lung Cancer
Primary: Feasibility of Using CH for Full-scale Future Research — 15; 6; 5 participants
Acne
Primary: Percent Change From Baseline to Week 12 in the Number of Inflamed Lesions. — -74.2; -73.0; -30.6 percentage of change from baseline